Centessa Pharmaceuticals | LinkedIn (original) (raw)

About us

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. We are headquartered in Boston, Massachusetts.

Industry

Biotechnology Research

Company size

51-200 employees

Type

Public Company

Founded

2021

Employees at Centessa Pharmaceuticals

Updates

Centessa management will be at the Guggenheim Healthcare Innovation Conference today. Listen to the fireside chat here: https://lnkd.in/eKB-cZWB
Today, Centessa announced additional interim data from the ongoing Phase 1 study of its novel orexin agonist, supporting its best-in-class potential for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the strength of these data, we have initiated a Phase 2a study in patients with NT1, NT2 and IH and expect data in all three indications in 2025. Read the full release here: https://lnkd.in/ePc9TYKj
Centessa is a proud sponsor of the Illuminate Hypersomnia initiative. As an advocate for sleep-wake disorders, we’re not only helping to shine a light on the challenges faced by those living with idiopathic hypersomnia (IH), but also working to develop a potentially transformative treatment to address their needs. Learn more about Centessa's orexin agonist program: https://lnkd.in/etK4De5m
We heard from so many of you living with IH and your care partners at the April 11 Illuminate Hypersomnia meeting and through the related survey. The IH community truly rose to shed light on what it’s like to live with IH. The EL-PFDD meeting summary report is now available at bit.ly/illuminate-IH. Thank you so much for sharing your unique experiences and perspectives to make this initiative possible. We know it is already making an impact with regulators, life science companies, researchers, and others interested in IH.#IHPFDD #IlluminateIH #idiopathichypersomnia #livingwithIH #livingwithidiopathichypersomnia #idiopathichypersomnolence #PFDD #patientfocused #sleepconsortium #thisisIH
7,037 followers
1mo Edited
Today, Centessa shared new preclinical data from non-human primate (NHP) studies of ORX142, an investigational, novel, orexin receptor 2 (OX2R) agonist being advanced for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative and psychiatric disorders, at European Sleep Research Society - Sleep Europe 2024. We are focused on rapidly moving ORX142, the second drug candidate from our growing pipeline of OX2R agonists, through IND-enabling studies. #SleepEuropeRead full release here: https://lnkd.in/emCdGfQF
Thank you Tatiana Corbitt and Katelynn O'Connell for joining our recent Town Hall! In recognition of World Narcolepsy Day, we were honored to host two inspiring patient advocates who shared their personal journeys with narcolepsy. We share their passion to drive awareness for both narcolepsy and other sleep-wake disorders and are committed to helping make a difference. #PatientAdvocacy #WorldNarcolepsyDay #CNTAOX2R
September 22nd is World Narcolepsy Day! Join Centessa in raising awareness and understanding about narcolepsy—a chronic sleep disorder that affects millions worldwide. Narcolepsy isn’t just about feeling sleepy; it involves sudden and uncontrollable episodes of falling asleep, cataplexy (sudden loss of muscle tone), and other challenging symptoms. Narcolepsy and other sleep-wake disorders impact daily life. Help shine a light on the experiences of those living with narcolepsy by recognizing World Narcolepsy Day. Together, we can make a difference! Learn more about how the Centessa team is advancing a pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists for the treatment of narcolepsy and idiopathic hypersomnia, as well as excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders. https://lnkd.in/etK4De5m #WorldNarcolepsyDay #NarcolepsyAwareness
Based on the positive interim data from the ongoing Phase 1 study reported today, Centessa plans to advance ORX750 into Phase 2 studies in patients with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, beginning in the fourth quarter of 2024. Centessa plans to further leverage these data to expedite the progression of its multi-asset orexin franchise to potentially treat excessive daytime sleepiness across multiple disorders. Read more here: https://lnkd.in/eyW74rkC

Join now to see what you are missing

Join now

Centessa Pharmaceuticals | LinkedIn (original) (raw)

About us

Employees at Centessa Pharmaceuticals

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding